Remove 2020 Remove Biosimilars Remove Insurance Coverage and Processing
article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top Performing Drug – Enbrel (June Edition)

PharmaShots

In 2020 and 2021, this decrease was driven by lower net selling price, unit demand, and unfavorable changes in inventory, partially offset by favorable changes to estimated sales deductions and inventory. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. Clinicaltrial.gov 4.

article thumbnail

Pharmacy Policy Updates for June 2025

Pharmacy Times

The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. Second, it does not address the core issues of higher prices, such as the use of rebates by insurers.